BOT 1.59% 32.0¢ botanix pharmaceuticals ltd

Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,096 Posts.
    lightbulb Created with Sketch. 267
    The announcement hints at BTX1204 being a potential blockbuster:

    "....Phase 1b patient study results suggests that BTX 1204 potentially has a broader mechanism of action than Eucrisa®, with substantial reduction in the key signs of atopic dermatitis already observed."

    Considering that with the figures associated with the Pfizer's transaction in 2016, BOT looks like one of the rarest finds on the ASX (or any other stock market really) a potential 100 bags from here - and that's only for AD.

    Time will tell, I'm starting my vacations early this year.
    Wishing all a Merry Xmas.
    Last edited by aburbe: 18/12/18
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
0.005(1.59%)
Mkt cap ! $707.4M
Open High Low Value Volume
31.5¢ 32.5¢ 31.0¢ $1.169M 3.655M

Buyers (Bids)

No. Vol. Price($)
9 274982 31.5¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 48600 2
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.